We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+8.62%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.71B
AUM Growth
+$201M
Cap. Flow
+$66M
Cap. Flow %
1.4%
Top 10 Hldgs %
37.6%
Holding
120
New
15
Increased
43
Reduced
17
Closed
23

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$135M
2
AZN icon
AstraZeneca
AZN
+$85.6M
3
BAX icon
Baxter International
BAX
+$72.7M
4
AVTR icon
Avantor
AVTR
+$60.9M
5
UNH icon
UnitedHealth
UNH
+$55.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$126M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$92.2M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$39.7M
4
EXAS
Exact Sciences
EXAS
+$35.2M
5
CMPS
Compass Pathways
CMPS
+$34.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Financials 0.5%
3 Technology 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSAC
76
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$5.04M 0.11%
520,000
– –
ARYD
77
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$4.96M 0.11%
500,000
– –
SNTI icon
78
Senti Biosciences Holdings
SNTI
$11.2M
$4.93M 0.1%
50,000
– –
SNCE
79
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$4.91M 0.1%
19,700
-300
-2% -$66.6K
BLSA
80
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.9M 0.1%
500,000
– –
PANA
81
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.85M 0.1%
500,000
– –
TRDA icon
82
Entrada Therapeutics
TRDA
$247M
$4.37M 0.09%
+255,000
New +$6.18M
WGS icon
83
GeneDx Holdings
WGS
$1.9B
$4.24M 0.09%
28,788
-21,515
-43% -$4.81M
OBIO icon
84
Orchestra BioMed
OBIO
$234M
$4.03M 0.09%
400,000
– –
MLTX icon
85
MoonLake Immunotherapeutics
MLTX
$1.58B
$3.96M 0.08%
400,000
– –
SLGC
86
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$3.84M 0.08%
330,000
– –
MRUS
87
DELISTED
Merus
MRUS
$3.27M 0.07%
+103,000
New +$2.91M
ONCS
88
DELISTED
OncoSec Medical Incorporated
ONCS
$2.83M 0.06%
133,864
– –
AKLI
89
DELISTED
Akili Inc
AKLI
$1.99M 0.04%
200,000
– –
PROK icon
90
ProKidney
PROK
$314M
$1.98M 0.04%
200,000
– –
DNAB
91
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
$1.98M 0.04%
200,000
– –
DNAD
92
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$1.96M 0.04%
200,000
– –
STTK icon
93
Shattuck Labs
STTK
$646M
$1.4M 0.03%
165,000
-1,860,000
-92% -$25.6M
TCRT icon
94
Alaunos Therapeutics
TCRT
$4.69M
$643K 0.01%
3,933
-16,067
-80% -$3.53M
SLGCW
95
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$220K ﹤0.01%
65,999
– –
NUVB.WS
96
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$189K ﹤0.01%
99,999
– –
MSACW
97
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$42K ﹤0.01%
57,770
– –
ACIU icon
98
AC Immune
ACIU
$231M
– –
-1,739,600
Closed -$11.7M
ATAI icon
99
AtaiBeckley Inc
ATAI
$2.66B
– –
-218,730
Closed -$3.23M
CMPS
100
Compass Pathways
CMPS
$1.48B
– –
-1,162,000
Closed -$34.7M
1 2 3
4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2021 Portfolio in Review

As of Q4 2021, Avidity Partners Management held 120 positions worth $4.71B, up 4.5% from $4.51B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Avidity Partners Management's Q4 2021 filing shows 15 new, 43 increased, 17 reduced and 23 closed positions. Its largest new stake was Elevance Health: 321,000 shares worth $149M. The largest sale was Vertex Pharmaceuticals, an estimated $126M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 85% a quarter earlier, followed by Financials and Technology.

  • Avidity Partners Management's largest Q4 2021 buy was Elevance Health: 321,000 shares worth $149M.
  • Avidity Partners Management added most to AstraZeneca in Q4 2021, an estimated $85.6M increase.
  • Avidity Partners Management's biggest Q4 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $126M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q4 2021, selling an estimated $92.2M.
  • Avidity Partners Management's ten largest holdings make up 38% of its $4.71B portfolio in Q4 2021.
  • Avidity Partners Management opened 15 new positions and closed 23 in Q4 2021.
  • Avidity Partners Management's portfolio value rose 4.5% quarter-over-quarter to $4.71B.

Based on Avidity Partners Management's 13F filing for Q4 2021, filed 14 Feb 2022.